Literature DB >> 2684057

Compliance in clinical trials.

T Pullar1, S Kumar, M Feely.   

Abstract

Compliance with treatment can be an important determinant of the outcome of clinical trials. To date there is no completely satisfactory method of measuring compliance and some of the most widely used methods are inadequate. The various methods of measuring compliance and how they have been applied to clinical trials are described, and improvements in the standard of the measurement and reporting of compliance in clinical trials are suggested.

Mesh：

Substances：

Year:  1989        PMID： 2684057      PMCID： PMC1003898          DOI： 10.1136/ard.48.10.871

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  32 in total

1.  The clinical trial.

Authors:  A B HILL
Journal:  N Engl J Med       Date:  1952-07-24       Impact factor: 91.245

Review 2.  Compliance in clinical trials: impact on design, analysis and interpretation.

Authors:  G W Pledger
Journal:  Epilepsy Res Suppl       Date:  1988

3.  The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community.

Authors:  R Cheung; C M Sullens; D Seal; J Dickins; P W Nicholson; A A Deshmukh; M J Denham; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

4.  Alcohol and response to treatment of gout.

Authors:  S H Ralston; H A Capell; R D Sturrock
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-11

5.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

6.  Minimal doses of digoxin: a new marker for compliance to medication.

Authors:  H Mäenpää; K Javela; J Pikkarainen; M Mälkönen; O P Heinonen; V Manninen
Journal:  Eur Heart J       Date:  1987-10       Impact factor: 29.983

7.  Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

Authors:  T Pullar; A J Birtwell; P G Wiles; A Hay; M P Feely
Journal:  Clin Pharmacol Ther       Date:  1988-11       Impact factor: 6.875

8.  The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy.

Authors:  T Pullar; S Peaker; M F Martin; H A Bird; M P Feely
Journal:  Br J Rheumatol       Date:  1988-10

9.  Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study.

Authors:  J J Belch; D Ansell; R Madhok; A O'Dowd; R D Sturrock
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

10.  A general method of compliance assessment using centralized pharmacy records. Description and validation.

Authors:  J F Steiner; T D Koepsell; S D Fihn; T S Inui
Journal:  Med Care       Date:  1988-08       Impact factor: 2.983
View more
  9 in total

1.  Dietary protein-induced increases in urinary calcium are accompanied by similar increases in urinary nitrogen and urinary urea: a controlled clinical trial.

Authors:  Jessica D Bihuniak; Christine A Simpson; Rebecca R Sullivan; Donna M Caseria; Jane E Kerstetter; Karl L Insogna
Journal:  J Acad Nutr Diet       Date:  2013-03       Impact factor: 4.910

2.  Comparison of methods to assess adherence to small-quantity lipid-based nutrient supplements (SQ-LNS) and dispersible tablets among young Burkinabé children participating in a community-based intervention trial.

Authors:  Souheila Abbeddou; Sonja Y Hess; Elizabeth Yakes Jimenez; Jérôme W Somé; Stephen A Vosti; Rosemonde M Guissou; Jean-Bosco Ouédraogo; Kenneth H Brown
Journal:  Matern Child Nutr       Date:  2015-12       Impact factor: 3.092

3.  Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance.

Authors:  Weining Shen; Jing Ning; Ying Yuan
Journal:  Stat Med       Date:  2015-03-10       Impact factor: 2.373

4.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Authors:  Bernard Vrijens; Gäbor Vincze; Paulus Kristanto; John Urquhart; Michel Burnier
Journal:  BMJ       Date:  2008-05-14

5.  Comparing the effects of sun exposure and vitamin D supplementation on vitamin D insufficiency, and immune and cardio-metabolic function: the Sun Exposure and Vitamin D Supplementation (SEDS) Study.

Authors:  Mica Hartley; Samuel Hoare; Fiona E Lithander; Rachel E Neale; Prue H Hart; Shelley Gorman; Peter Gies; Jill Sherriff; Ashwin Swaminathan; Lawrence J Beilin; Trevor A Mori; Laura King; Lucinda J Black; Kushani Marshall; Fan Xiang; Candy Wyatt; Kerryn King; Terry Slevin; Nirmala Pandeya; Robyn M Lucas
Journal:  BMC Public Health       Date:  2015-02-10       Impact factor: 3.295

6.  An internal pilot study for a randomized trial aimed at evaluating the effectiveness of iron interventions in children with non-anemic iron deficiency: the OptEC trial.

Authors:  Kawsari Abdullah; Kevin E Thorpe; Eva Mamak; Jonathon L Maguire; Catherine S Birken; Darcy Fehlings; Anthony J Hanley; Colin Macarthur; Stanley H Zlotkin; Patricia C Parkin
Journal:  Trials       Date:  2015-07-14       Impact factor: 2.279

7.  High adherence and low dropout rate in a virtual clinical study of atopic dermatitis through weekly reward-based personalized genetic lifestyle reports.

Authors:  Zarqa Ali; Kathryn Anderson; Andrei Chiriac; Anders Daniel Andersen; Ari Pall Isberg; Fernando Gesto Moreno; Aleksander Eiken; Simon Francis Thomsen; John Robert Zibert
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

Review 8.  Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.

Authors:  Menno T Pruijm; Marc P Maillard; Michel Burnier
Journal:  Vasc Health Risk Manag       Date:  2008

9.  Marginal Impact of Brown Seaweed Ascophyllum nodosum and Fucus vesiculosus Extract on Metabolic and Inflammatory Response in Overweight and Obese Prediabetic Subjects.

Authors:  Marlène Vodouhè; Julie Marois; Valérie Guay; Nadine Leblanc; Stanley John Weisnagel; Jean-François Bilodeau; Hélène Jacques
Journal:  Mar Drugs       Date:  2022-02-26       Impact factor: 5.118
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.